REFERRAL CRITERIA AND CLINICAL APPLICATION OF PREVENTIVE BRCA1/BRCA2 GENETIC TESTING IN BREAST AND OVARIAN CANCER: A NARRATIVE REVIEW

Authors

DOI:

https://doi.org/10.31435/ijitss.4(52).2026.6842

Keywords:

BRCA1, BRCA2, Hereditary Breast And Ovarian Cancer (HBOC), Next-Generation Sequencing (NGS), PARP Inhibitors, Prophylactic Salpingo-Oophorectomy, Risk-Reducing Mastectomy, Cascade Testing

Abstract

Background: Patients inheriting BRCA1 or BRCA2 mutations face significantly elevated risks of breast, ovarian, and pancreatic cancers, and melanoma. Identifying high-risk individuals enables timely prevention and selection of targeted therapies.

Objectives: This review summarizes genetic testing referral guidelines, discusses BRCA1/2 roles in DNA repair, presents modern diagnostic methods, and addresses preventive strategies for mutation carriers.

Methods/Scope: A comprehensive examination of clinical practice guidelines (including NCCN criteria), diagnostic paradigms (NGS, MLPA, Sanger sequencing), risk assessment models, targeted therapies, surgical risk-reduction strategies, and lifestyle factors was conducted.

Results/Discussion: Genetic testing enables early carrier identification for prevention and qualifies cancer patients for targeted PARP inhibitor therapy. Next-Generation Sequencing (NGS) has replaced Real-time PCR—which only detected common founder mutations—achieving diagnostic sensitivity above 99%. Qualification relies on pedigree analysis and risk evaluation. Prophylactic bilateral mastectomy and salpingo-oophorectomy reduce breast and gynecological cancer risks by 90–95%, while intensified surveillance with MRI ensures early detection. Young BRCA1/2 carriers face challenges regarding fertility preservation, surgical menopause, altered body image, and psychological stress, requiring multi-specialty care. Male carriers also require structured prostate and breast monitoring.

Conclusion: Early identification of BRCA1/2 carriers by primary care physicians, gynecologists, and oncologists is essential for optimizing risk reduction, surveillance, and personalized oncology. Population-wide screening in individuals with unburdened family histories remains unindicated.

References

Petrucelli, N., Daly, M. B., & Pal, T. (1998, September 4; updated March 25, 2026). BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. In M. P. Adam, S. Bick, G. M. Mirzaa, et al. (Eds.), GeneReviews® [Internet] (1993–2026). University of Washington, Seattle. https://www.ncbi.nlm.nih.gov/books/NBK1247/

Sessa, C., Balmaña, J., Bober, S. L., Cardoso, M. J., Colombo, N., Curigliano, G., et al. (2023). Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO clinical practice guideline. Ann Oncol, 34(1), 33–47.

Committee on Practice Bulletins-Gynecology, Committee on Genetics, & Society of Gynecologic Oncology. (2017). ACOG practice bulletin no. 182: Hereditary breast and ovarian cancer syndrome [Reaffirmed 2024]. Obstet Gynecol, 130(3), e110–e126. https://doi.org/10.1097/AOG.0000000000002296

Obwieszczenie Ministra Zdrowia z dnia 6 września 2024 r. w sprawie kluczowych zaleceń w zakresie opieki onkologicznej dotyczących organizacji i postępowania klinicznego w raku piersi. (2024). Dziennik Urzędowy Ministra Zdrowia, poz. 71. https://dziennikmz.mz.gov.pl/DUM_MZ/2024/71/oryginal/akt.pdf

National Comprehensive Cancer Network. (2026). NCCN guidelines for Poland: Invasive breast cancer (comprehensive version 3.2026). https://www.nccn.org/guidelines/category_1

National Comprehensive Cancer Network. (2026). NCCN clinical practice guidelines in oncology: Breast cancer (version 9.2026). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

Tysarowski, A., Szumera-Ciećkiewicz, A., Marszałek, A., Kowalik, A., Seliga, K., Bidziński, M., et al. (2023). Molecular diagnostics of cancers practical approach. NOWOTWORY J Oncol, 73(3), 174–186. https://doi.org/10.5603/NJO.2023.0028

Jassem, J., Krzakowski, M., Bobek-Billewicz, B., Duchnowska, R., Jeziorski, A., Olszewski, W., et al. (2018). Breast cancer. Oncol Clin Pract, 14(4), 187–210. https://doi.org/10.5603/OCP.2018.0027

National Cancer Institute. (2020). BRCA gene mutations: Cancer risk and genetic testing [Internet]. Retrieved October 26, 2026, from https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet

Centers for Disease Control and Prevention. (2023). Cascade testing for hereditary breast and ovarian cancer [Internet]. Retrieved October 26, 2026, from https://www.cdc.gov/genomics/disease/breast_ovarian_cancer/cascade_testing.htm

Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., et al. (2021). Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 19(1), 77–102. https://doi.org/10.6004/jnccn.2021.0001

Wielgoś, M., Krzakowski, M., Czajkowski, K., Giermek, J., Jagiełło-Gruszfeld, A., Wojciechowska-Lampka, E., et al. (2016). Standardy postępowania w przypadkach choroby nowotworowej u kobiety w ciąży. Część I. Wiadomości ogólne: Epidemiologia, diagnostyka, leczenie, poradnictwo genetyczne. Ginekol Perinatol Pract. https://share.google/rwXdv7AZJb8gEkXRu

Kushi, L. H., Doyle, C., McCullough, M., Rock, C. L., Demark-Wahnefried, W., Bandera, E. V., et al. (2012). American cancer society guidelines on nutrition and physical activity for cancer prevention: Reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin, 62(1), 30–67. https://doi.org/10.3322/caac.20140

Cheng, H. H., Giri, V. N., Goggins, M., Yurgelun, M. B., Karlan, B. Y., Norquist, B. S., et al. (2026). NCCN guidelines insights: Genetic/familial high-risk assessment: Breast, ovarian, pancreatic, and prostate, version 2.2026. J Natl Compr Canc Netw, 24(2), 2–10. https://doi.org/10.6004/jnccn.2026.0007

Roy, R., Chun, J., Powell, S. N. (2011). BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat Rev Cancer, 12(1), 68–78. https://doi.org/10.1038/nrc3181

Lord, C. J., Ashworth, A. (2017). PARP inhibitors: Synthetic lethality in the clinic. Science, 355(6330), 1152–1158. https://doi.org/10.1126/science.amc1080

Robson, M., Im, S. A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., et al. (2017). Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med, 377(6), 523–533. https://doi.org/10.1056/NEJMoa1706450

Tutt, A. N. J., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., et al. (2021). Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med, 384(25), 2394–2405. https://doi.org/10.1056/NEJMoa2105215

Medycyna Praktyczna. (2017). Pacjenci z grupy dużego dziedzicznego ryzyka zachorowania na raka piersi i raka jajnika (w tym nowotwory BRCA-zależne) – badania, opieka i profilaktyka [Internet]. Retrieved October 26, 2026, from https://www.mp.pl/ginekologia/ginekologia-onkologiczna/155053

Zwrotnik Raka. (2023). Mutacje genów BRCA1 i BRCA2 – dziedziczny rak piersi i rak jajnika [Internet]. Retrieved October 26, 2026, from https://www.zwrotnikraka.pl/mutacje-genow-brca1-i-brca2-dziedziczny-rak-piersi-i-rak-jajnika/

Downloads

Published

2026-11-06

How to Cite

Janiszek, K., Iwaniec, L., Jabłońska, W., Uchański, M., Januszaniec, I., Mróz, A., Bonder, A., Kiszka, M., Janicka, J., & Janasik, J. (2026). REFERRAL CRITERIA AND CLINICAL APPLICATION OF PREVENTIVE BRCA1/BRCA2 GENETIC TESTING IN BREAST AND OVARIAN CANCER: A NARRATIVE REVIEW. International Journal of Innovative Technologies in Social Science, 1(4(52). https://doi.org/10.31435/ijitss.4(52).2026.6842

Most read articles by the same author(s)